Microba Life Sciences Limited (MAP) AI Stock Analysis

• Market Cap: AU$48.72M
• Dividend Yield: N/A
• Average Volume (3M): 469.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 29.60%
• EPS Growth: 33.00%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.02
• Shares Outstanding: 608,963,000
• 10 Day Avg. Volume: 548,444
• 30 Day Avg. Volume: 469,774
• PEG Ratio: 0.08
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 2.43
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.21
• Price Target Upside: 162.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.02
• Revenue Forecast (FY): AU$18.83M

• Rating: 49 Neutral
• Price Target: AU$0.08 ▲(0.00% Upside)
• Action: Reiterated Date: 01/17/26
• Date: Action: Reiterated 01/17/26

The score is primarily constrained by weak financial performance, including falling revenue and persistent losses with negative operating cash flow. Technical indicators are comparatively supportive (price above key moving averages and positive MACD), but valuation is difficult to assess given the negative P/E and no dividend data.

Positive Factors

Low leverage (debt-to-equity 0.10)

Very low debt-to-equity (0.10) gives durable financial flexibility: lower interest burden and greater ability to fund R&D or absorb revenue volatility without immediate refinancing. This structural strength supports long-term product development and partnership execution.

Positive free cash flow growth

Free cash flow growing (4.68%) and exceeding net income indicates the business can generate cash beyond accounting losses. Over months this supports operational runway, selective reinvestment in sequencing capacity and analytics, and reduces reliance on equity raises if sustained.

Platform-based, diversified revenue streams

A platform combining sequencing, bioinformatics and test services creates multiple durable revenue channels (direct tests, B2B services, collaborations). This structural diversity helps capture recurring test demand, margin-enhancing service contracts, and R&D partnerships over the medium term.

Negative Factors

Declining revenue

A steep revenue decline (-24.28%) is a durable risk: shrinking top line reduces scale benefits, limits R&D and marketing investment, and increases pressure on fixed-cost absorption. Continued contraction would hinder path to sustainable profitability and commercial momentum.

Persistent negative profitability

Negative EBIT/EBITDA and net profit margins signal structural unprofitability: ongoing losses erode retained earnings and return on equity, necessitating external funding or structural cost reductions to reach sustainable margins and support longer-term commercial expansion.

Negative operating cash flow

Persistent negative operating cash flow, despite FCF growth, indicates operational cash generation issues (working capital, timing, or core margin shortfalls). Over months this raises liquidity risk and the likelihood of financings that could dilute shareholders or constrain strategic initiatives.

Microba Life Sciences Limited Business Overview & Revenue Model

Company Description

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.

How the Company Makes Money

Microba Life Sciences makes money primarily by selling microbiome-related products and services. Key revenue streams include: (1) consumer- and clinician-facing gut microbiome tests, where the company earns revenue per test sold (typically including sample kit, laboratory processing, sequencing, and reporting/insights); (2) business-to-business laboratory, sequencing, and bioinformatics services provided to researchers, healthcare organisations, and life-science companies, where Microba earns fees for processing samples, generating microbiome datasets, and delivering analytical outputs; and (3) collaborations and contracted work that leverage its microbiome profiling platform and datasets to support external R&D programs (e.g., study services and other project-based engagements), generating service fees and potentially milestone or other payments where contract terms include them. Specific details on named partnerships, pricing, and the exact mix of revenue by segment are null.

Microba Life Sciences Limited Financial Statement Overview

Summary

Weak fundamentals: revenue is declining (-24.28%) and profitability is negative (net profit, EBIT, and EBITDA margins all below zero). Balance sheet leverage is low (debt-to-equity 0.10), but negative ROE and negative operating cash flow indicate ongoing operating strain despite slightly positive free cash flow growth.

Income Statement

Microba Life Sciences Limited has experienced declining revenue growth, with a negative growth rate of -24.28% in the latest period. The company is operating at a loss, as indicated by negative net profit, EBIT, and EBITDA margins. Despite a relatively stable gross profit margin, the overall profitability is weak due to high operating expenses.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio of 0.10, indicating low leverage and financial risk. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests a strong equity base relative to total assets, but profitability remains a concern.

Cash Flow

Microba Life Sciences Limited has a positive free cash flow growth rate of 4.68%, but operating cash flow remains negative. The free cash flow to net income ratio is above 1, indicating that free cash flow exceeds net income, which is a positive sign. However, the negative operating cash flow coverage ratio highlights cash flow challenges.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	14.90M	15.67M	12.09M	5.42M	4.69M	3.73M
Gross Profit	-2.96M	7.44M	5.91M	-6.77M	2.37M	-5.30M
EBITDA	-21.64M	-10.51M	-17.10M	-17.07M	-9.86M	-6.28M
Net Income	-19.75M	-14.94M	-19.94M	-12.68M	-11.47M	-7.52M
Balance Sheet
Total Assets	43.35M	47.44M	58.04M	46.95M	39.48M	18.49M
Cash, Cash Equivalents and Short-Term Investments	11.27M	11.74M	20.89M	32.04M	30.79M	13.03M
Total Debt	3.31M	3.23M	1.58M	1.14M	1.33M	269.02K
Total Liabilities	12.27M	14.94M	16.82M	8.23M	5.94M	3.55M
Stockholders Equity	30.18M	32.49M	41.22M	38.57M	33.54M	14.94M
Cash Flow
Free Cash Flow	-15.38M	-14.91M	-19.95M	-15.43M	-12.32M	-7.85M
Operating Cash Flow	-15.05M	-12.01M	-15.57M	-12.39M	-10.45M	-7.18M
Investing Cash Flow	-3.39M	-2.83M	-13.95M	-3.00M	-1.73M	-522.48K
Financing Cash Flow	12.34M	5.58M	18.39M	16.68M	29.22M	13.84M

Microba Life Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.28 is Neutral, neither overbought nor oversold. The STOCH value of 65.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MAP.

Microba Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	60 Neutral	AU$56.13M	10.72	72.82%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAP	49 Neutral	AU$48.72M	-1.06	-63.04%	―	29.60%	33.00%
LDX	49 Neutral	AU$227.35M	-7.39	-164.12%	―	12.96%	40.81%
BDX	42 Neutral	AU$35.39M	-2.45	-164.22%	―	―	23.85%
GSS	41 Neutral	AU$17.04M	-2.23	-23.93%	―	62.81%	16.37%
IIQ	38 Underperform	AU$51.38M	-3.02	-37.14%	―	2.33%	12.50%

Microba Life Sciences Limited Corporate Events

Microba boosts core microbiome testing as it exits legacy products and targets FY26 break-even

Microba Life Sciences reported strong operational progress for the half year to 31 December 2025, with 10,258 core tests sold globally, a 113% increase on the prior period, and an annualised run rate above 21,300 tests as it targets more than 24,000 tests in FY26. Growth was driven by record adoption of Microbiome Explorer in Australia, rapid uptake in the United Kingdom where it now accounts for all GI tests sold, and steady MetaPanel adoption, while all legacy products have been discontinued.

The company completed a major brand and laboratory consolidation, introduced AI tools to lift efficiency, released new product features to support high-volume clinician use, and expects more than $1 million in cost savings over 24 months alongside $2 million in annual staff cost reductions. Although total revenue fell 9% to $7.32 million due to legacy product exit, core testing and growth product revenue more than doubled, the therapeutics portfolio has moved into an active partnering phase, and management says Microba remains on track to reach regional break-even by the end of FY26, strengthening its position in an emerging diagnostic category.

The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.29 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba Launches Q2 FY26 Investor Webinar and Expands Interactive Investor Hub

Microba Life Sciences has released its Q2 FY26 investor presentation and scheduled a quarterly investor webinar to be hosted by CEO Dr Luke Reid on 29 January 2026, offering investors a detailed update on the company’s performance and activities. The company is also promoting its interactive Investor Hub as a central platform for shareholders and interested parties to register for the webinar, submit questions directly to management, access presentation materials and recordings, and receive notifications of future reports and key announcements, underscoring an increased focus on investor engagement and transparency.

The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.

Microba to Release Q2 FY26 Report and Host Investor Webinar

Microba Life Sciences Limited has announced it will release its Q2 FY26 Quarterly Activities Report, cash flow statement and investor presentation on 29 January 2026, alongside hosting a quarterly investor webinar presented by CEO Dr Luke Reid. The company is directing investors to its interactive Investor Hub for webinar registration, advance question submission and ongoing access to announcements, reflecting a push to deepen engagement with shareholders and improve transparency around its operational and financial performance.

The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.